title: Treatment trial of oxiracetam in Alzheimer's disease.
abstract: Twenty-four carefully assessed patients with probable Alzheimer's disease were enrolled in a double-blind, placebo-controlled treatment study of oxiracetam, a nootropic agent reported to improve memory performance in patients with dementia. A broad battery of neuropsychological tests failed to reveal any improvement in the treated group or in any treated patient when individual test scores were analyzed. These findings indicate that oxiracetam is ineffective in reducing cognitive impairment due to Alzheimer's disease.
authors.affiliation: Department of Neurology, Emory University School of Medicine.
authors.forename: R C
authors.initials: RC
authors.lastname: Green
authors.forename: F C
authors.initials: FC
authors.lastname: Goldstein
authors.forename: A P
authors.initials: AP
authors.lastname: Auchus
authors.forename: R
authors.initials: R
authors.lastname: Presley
authors.forename: W S
authors.initials: WS
authors.lastname: Clark
authors.forename: L
authors.initials: L
authors.lastname: Van Tuyl
authors.forename: J
authors.initials: J
authors.lastname: Green
authors.forename: S M
authors.initials: SM
authors.lastname: Hersch
authors.forename: H R
authors.initials: HR
authors.lastname: Karp
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology; D004311:Double-Blind Method; D006801:Humans; D009483:Neuropsychological Tests; D010919:Placebos; D011759:Pyrrolidines / Q000008:administration & dosage*
chemical_list: D010919:Placebos; D011759:Pyrrolidines; C040619:oxiracetam